Open AccessFactors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer
Author(s) -
Philip A. Rowlings,
Stephanie Williams,
Karen H. Antman,
Karen K. Fields,
Joseph W. Fay,
Elizabeth Reed,
Corey J. Pelz,
John P. Klein,
Kathleen A. Sobocinski,
Michael J. Kennedy,
César O. Freytes,
Philip L. McCarthy,
Roger H. Herzig,
Edward A. Stadtmauer,
Hillard M. Lazarus,
Andrew L. Pecora,
Jacob D. Bitran,
Steven N. Wolff,
Robert Peter Gale,
Jamés O. Armitage,
William P. Vaughan,
Gary Spitzer,
Mary M. Horowitz
Publication year - 1999
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.282.14.1335
Subject(s) - medicine , hazard ratio , breast cancer , surgery , chemotherapy , transplantation , metastatic breast cancer , proportional hazards model , oncology , hematopoietic stem cell transplantation , cancer , confidence interval
Women with breast cancer are the most frequent recipients of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autotransplants) in North America. Despite widespread use, controversy exists about the benefits of and appropriate patients for this therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom